Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 07, 2023 16:02 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
March 01, 2023 16:17 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
February 27, 2023 16:05 ET
|
Revolution Medicines, Inc.
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
February 21, 2023 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Revolution Medicines to Participate in Upcoming Investor Conferences
February 02, 2023 07:00 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
LEON successfully completes development of its innovative reactor for more efficient production of lipid nanoparticles
January 03, 2023 09:00 ET
|
leon-nanodrugs GmbH
LEON achieved superior accuracy in development of its proprietary reactor, facilitating exceptional inter-device reproducibility of particle size and distribution, and thus seamless process transfer,...
Precision Medicine Market Size to Hit USD 157.46 Billion by 2030 at 11.9% CAGR – Report by Market Research Future (MRFR)
November 14, 2022 10:15 ET
|
Market Research Future
New York, USA, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Precision Medicine Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Precision Medicine Market...
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress
November 07, 2022 16:05 ET
|
Revolution Medicines, Inc.
Dose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor) Completed successful equity financing to...
Hemisphere GNSS Introduces GradeMetrix® Loader Kit
October 26, 2022 23:00 ET
|
Hemisphere GNSS (989444)
MUNICH, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Hemisphere GNSS, Inc. announces the release of the GradeMetrix® Loader solution. Recognizing the growing global demand and versatility of the loader,...
Hemisphere GNSS Introduces GradeMetrix® Scraper
October 25, 2022 09:00 ET
|
Hemisphere GNSS (989444)
MUNICH, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Hemisphere GNSS, Inc. announces the release of the GradeMetrix® Scraper Solution for pull pan and belly pan scrapers. "We believe by introducing...